Tofersen was recommended for European approval in Feb 2024 to treat SOD1 ALS (https://www.ema.europa.eu/en/medicines/human/EPAR/qalsody, accessed on 5 May 2024). Here, SOD1 is linked to amyotrophic lateral sclerosis.